Cargando…
A new aggressive xenograft model of human colon cancer using cancer-associated fibroblasts
BACKGROUND: Colorectal cancer is the second leading cause of cancer death. Almost half of the patients present recurrence within 5 years after the treatment of the primary tumor, the majority, with metastasis. On the other hand, in the search for new animal models that simulate metastatic cancer, it...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PeerJ Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275677/ https://www.ncbi.nlm.nih.gov/pubmed/32547853 http://dx.doi.org/10.7717/peerj.9045 |
_version_ | 1783542835380748288 |
---|---|
author | Fernando-Macías, Ester Fernández-García, Maria Teresa García-Pérez, Eva Porrero Guerrero, Belén López-Arévalo, Camilo Rodríguez-Uría, Raquel Sanz-Navarro, Sandra Vázquez-Villa, José Fernando Muñíz-Salgueiro, María Carmen Suárez-Fernández, Laura Galván, José A. Barneo-Caragol, Clara García-Ocaña, Marcos de los Toyos, Juan R. Barneo-Serra, Luis |
author_facet | Fernando-Macías, Ester Fernández-García, Maria Teresa García-Pérez, Eva Porrero Guerrero, Belén López-Arévalo, Camilo Rodríguez-Uría, Raquel Sanz-Navarro, Sandra Vázquez-Villa, José Fernando Muñíz-Salgueiro, María Carmen Suárez-Fernández, Laura Galván, José A. Barneo-Caragol, Clara García-Ocaña, Marcos de los Toyos, Juan R. Barneo-Serra, Luis |
author_sort | Fernando-Macías, Ester |
collection | PubMed |
description | BACKGROUND: Colorectal cancer is the second leading cause of cancer death. Almost half of the patients present recurrence within 5 years after the treatment of the primary tumor, the majority, with metastasis. On the other hand, in the search for new animal models that simulate metastatic cancer, it has been suggested that fibroblasts immersed in the peritumoral stroma (cancer-associated fibroblasts (CAFs)), play a relevant role in the development of cancer. The objective of this study was to identify an adequate animal model to study metastatic colon cancer and the application of new treatments. METHODS: Human CAFs and normal fibroblasts (NF) for transplant and culture were obtained from surgical fresh samples of patients with adenocarcinoma of sigmoid colon. Stromal cell purity was evaluated by morphology and immunostaining with vimentin (VIM) as a fibroblast marker and anti-proColXIα1 as a specific human CAF marker. Phenotypic characterization of cultured stromal cells was performed by co-staining with mesenchymal and epithelial cell markers. For identification in mice, human CAFs were labeled with the PKH26 red fluorescence dye. Cell line HT-29 was used as tumor cells. Transplant in the head of the pancreas of 34 SCID mice was performed in four different groups, as follows: I. 150,000 CAFS (n = 12), IIa. 1.5 million HT29 cells (n = 7), IIb. 150,000 NF+1.5 million HT29 cells (n = 5), III. 150,000 CAFS+1.5 million HT29 cells (n = 10). After euthanasia performed one month later, histological analysis was made using hematoxylin–eosin and anti-proColXIα1. A histopathological score system based on three features (tumor volume, desmoplasia and number of metastasized organs) was established to compare the tumor severity. RESULTS: The CAFs and NF cultured were proColXIα1+/VIM+, proColXIα1/alphaSMA+ and proColXIα1+/CK19+ in different proportions without differences among them, but the CAFs growth curve was significantly larger than that of the NF (p < 0.05). No tumor developed in those animals that only received CAFs. When comparing group II (a + b) vs. group III, both groups showed 100% hepatic metastases. Median hepatic nodules, tumor burden, lung metastases and severity score were bigger in group III vs group II (a + b), although without being significant, except in the case of the median tumor volume, that was significantly higher in group III (154.8 (76.9–563.2) mm(3)) vs group II (46.7 (3.7–239.6) mm(3)), p = 0.04. A correlation was observed between the size of the tumor developed in the pancreas and the metastatic tumor burden in the liver and with the severity score. CONCLUSION: Our experiments demonstrate that cultured CAFs have a higher growth than NF and that when human CAFs are associated to human tumor cells, larger tumors with liver and lung metastases are generated than if only colon cancer cells with/without NF are transplanted. This emphasizes the importance of the tumor stroma, and especially the CAFs, in the development of cancer. |
format | Online Article Text |
id | pubmed-7275677 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | PeerJ Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72756772020-06-15 A new aggressive xenograft model of human colon cancer using cancer-associated fibroblasts Fernando-Macías, Ester Fernández-García, Maria Teresa García-Pérez, Eva Porrero Guerrero, Belén López-Arévalo, Camilo Rodríguez-Uría, Raquel Sanz-Navarro, Sandra Vázquez-Villa, José Fernando Muñíz-Salgueiro, María Carmen Suárez-Fernández, Laura Galván, José A. Barneo-Caragol, Clara García-Ocaña, Marcos de los Toyos, Juan R. Barneo-Serra, Luis PeerJ Oncology BACKGROUND: Colorectal cancer is the second leading cause of cancer death. Almost half of the patients present recurrence within 5 years after the treatment of the primary tumor, the majority, with metastasis. On the other hand, in the search for new animal models that simulate metastatic cancer, it has been suggested that fibroblasts immersed in the peritumoral stroma (cancer-associated fibroblasts (CAFs)), play a relevant role in the development of cancer. The objective of this study was to identify an adequate animal model to study metastatic colon cancer and the application of new treatments. METHODS: Human CAFs and normal fibroblasts (NF) for transplant and culture were obtained from surgical fresh samples of patients with adenocarcinoma of sigmoid colon. Stromal cell purity was evaluated by morphology and immunostaining with vimentin (VIM) as a fibroblast marker and anti-proColXIα1 as a specific human CAF marker. Phenotypic characterization of cultured stromal cells was performed by co-staining with mesenchymal and epithelial cell markers. For identification in mice, human CAFs were labeled with the PKH26 red fluorescence dye. Cell line HT-29 was used as tumor cells. Transplant in the head of the pancreas of 34 SCID mice was performed in four different groups, as follows: I. 150,000 CAFS (n = 12), IIa. 1.5 million HT29 cells (n = 7), IIb. 150,000 NF+1.5 million HT29 cells (n = 5), III. 150,000 CAFS+1.5 million HT29 cells (n = 10). After euthanasia performed one month later, histological analysis was made using hematoxylin–eosin and anti-proColXIα1. A histopathological score system based on three features (tumor volume, desmoplasia and number of metastasized organs) was established to compare the tumor severity. RESULTS: The CAFs and NF cultured were proColXIα1+/VIM+, proColXIα1/alphaSMA+ and proColXIα1+/CK19+ in different proportions without differences among them, but the CAFs growth curve was significantly larger than that of the NF (p < 0.05). No tumor developed in those animals that only received CAFs. When comparing group II (a + b) vs. group III, both groups showed 100% hepatic metastases. Median hepatic nodules, tumor burden, lung metastases and severity score were bigger in group III vs group II (a + b), although without being significant, except in the case of the median tumor volume, that was significantly higher in group III (154.8 (76.9–563.2) mm(3)) vs group II (46.7 (3.7–239.6) mm(3)), p = 0.04. A correlation was observed between the size of the tumor developed in the pancreas and the metastatic tumor burden in the liver and with the severity score. CONCLUSION: Our experiments demonstrate that cultured CAFs have a higher growth than NF and that when human CAFs are associated to human tumor cells, larger tumors with liver and lung metastases are generated than if only colon cancer cells with/without NF are transplanted. This emphasizes the importance of the tumor stroma, and especially the CAFs, in the development of cancer. PeerJ Inc. 2020-06-03 /pmc/articles/PMC7275677/ /pubmed/32547853 http://dx.doi.org/10.7717/peerj.9045 Text en © 2020 Fernando-Macías et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited. |
spellingShingle | Oncology Fernando-Macías, Ester Fernández-García, Maria Teresa García-Pérez, Eva Porrero Guerrero, Belén López-Arévalo, Camilo Rodríguez-Uría, Raquel Sanz-Navarro, Sandra Vázquez-Villa, José Fernando Muñíz-Salgueiro, María Carmen Suárez-Fernández, Laura Galván, José A. Barneo-Caragol, Clara García-Ocaña, Marcos de los Toyos, Juan R. Barneo-Serra, Luis A new aggressive xenograft model of human colon cancer using cancer-associated fibroblasts |
title | A new aggressive xenograft model of human colon cancer using cancer-associated fibroblasts |
title_full | A new aggressive xenograft model of human colon cancer using cancer-associated fibroblasts |
title_fullStr | A new aggressive xenograft model of human colon cancer using cancer-associated fibroblasts |
title_full_unstemmed | A new aggressive xenograft model of human colon cancer using cancer-associated fibroblasts |
title_short | A new aggressive xenograft model of human colon cancer using cancer-associated fibroblasts |
title_sort | new aggressive xenograft model of human colon cancer using cancer-associated fibroblasts |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275677/ https://www.ncbi.nlm.nih.gov/pubmed/32547853 http://dx.doi.org/10.7717/peerj.9045 |
work_keys_str_mv | AT fernandomaciasester anewaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT fernandezgarciamariateresa anewaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT garciaperezeva anewaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT porreroguerrerobelen anewaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT lopezarevalocamilo anewaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT rodriguezuriaraquel anewaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT sanznavarrosandra anewaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT vazquezvillajosefernando anewaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT munizsalgueiromariacarmen anewaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT suarezfernandezlaura anewaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT galvanjosea anewaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT barneocaragolclara anewaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT garciaocanamarcos anewaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT delostoyosjuanr anewaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT barneoserraluis anewaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT fernandomaciasester newaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT fernandezgarciamariateresa newaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT garciaperezeva newaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT porreroguerrerobelen newaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT lopezarevalocamilo newaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT rodriguezuriaraquel newaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT sanznavarrosandra newaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT vazquezvillajosefernando newaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT munizsalgueiromariacarmen newaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT suarezfernandezlaura newaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT galvanjosea newaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT barneocaragolclara newaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT garciaocanamarcos newaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT delostoyosjuanr newaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts AT barneoserraluis newaggressivexenograftmodelofhumancoloncancerusingcancerassociatedfibroblasts |